Everything below concerns triple agonist. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2025-08-31. Where a claim depends on a specific study, the study is described rather than over-claimed.
Retatrutide is an investigational peptide studied for obesity and type 2 diabetes. It is a single synthetic molecule designed to activate three metabolic receptors simultaneously. The compound belongs to the incretin mimetic family, a group of peptides that imitate gut hormones involved in appetite and glucose control. Its research code is LY3437943, and it remains under clinical study rather than cleared for routine medical use.
Acting as a triple agonist, the molecule binds the GLP-1, GIP, and glucagon receptors. GLP-1 activity slows gastric emptying and dampens appetite, while GIP signaling contributes to insulin sensitivity and fat metabolism. Glucagon receptor engagement raises energy expenditure and encourages fat breakdown, although it can also elevate blood glucose. Combining three pathways is intended to yield larger weight reduction than single or dual agonists, and researchers continue to examine how the balance among them shapes tolerability.
Pharmacologically, retatrutide acts as a triple agonist at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor. Activation of the first two receptors is associated with improved insulin secretion and reduced appetite. The glucagon receptor component is thought to increase energy expenditure, a mechanism that distinguishes this molecule from dual-agonist compounds. Researchers continue to investigate how the three activities interact and whether the combined profile offers advantages that justify additional clinical testing.
Several questions about the compound remain unresolved. The durability of weight reduction after treatment stops, the frequency of gastrointestinal side effects, and the long-term cardiovascular profile are topics of ongoing study. Regulatory submissions and phase 3 trial outcomes have not been fully reported in the public literature. Because most available data come from controlled trials rather than general-population use, conclusions about effectiveness outside study settings are provisional. The distinction between established findings and open questions matters when interpreting early coverage of the drug.
| Property | Value | Notes |
|---|---|---|
| Molecular weight | Approximately 4,700 Da | Peptide of roughly forty amino acids |
| Receptor targets | GLP-1, GIP, glucagon | Triple agonist class |
| Research code | LY3437943 | Internal development designation |
| Compound class | Incretin mimetic peptide | Synthetic, not a biologic extract |
| Development status | Investigational | No general regulatory approval |
Clinical development has advanced through phase 2 trials in adults with obesity and type 2 diabetes. Reported phase 2 results described substantial average weight reduction over roughly forty-eight weeks of weekly dosing. A phase 3 program is ongoing to confirm efficacy and assess long-term safety. Because the compound has not received regulatory approval, it is not available as a prescription product. Public discussion of retatrutide often conflates trial findings with marketed status, an important distinction when interpreting coverage of the topic.
Retatrutide is a synthetic peptide developed as a single molecule that activates three distinct hormone receptors: GLP-1, GIP, and glucagon. The compound carries the internal designation LY3437943 and was engineered by modifying the backbone of glucose-dependent insulinotropic polypeptide. Its sequence incorporates non-natural amino acids and a fatty acid side chain that extends circulation time. The triple-agonist design aims to combine appetite suppression, improved insulin response, and increased energy expenditure in one agent. Published reports describe it as an investigational product rather than an approved medicine.
The intended pharmacology combines three signals in one molecule. GLP-1 receptor activation reduces appetite and slows gastric emptying, effects already exploited by approved incretin-based therapies. GIP receptor engagement is associated with improved insulin sensitivity and with direct effects on adipose tissue, although how much it contributes to overall outcomes is still debated. Glucagon receptor agonism raises energy expenditure and supports hepatic lipid handling, a mechanism that also tends to increase glucose output. The triple profile is hypothesized to produce a larger metabolic effect than single or dual agonism, but the relative weight of each receptor in humans is not settled.
Human evidence remains limited to controlled studies. A phase 2 trial in adults with obesity reported large, dose-dependent reductions in body weight over 48 weeks, with gastrointestinal events as the most frequently recorded adverse effect. Phase 3 programs designated TRIUMPH, for obesity, and TRANSCEND, for type 2 diabetes, are intended to confirm efficacy and to characterize safety in larger populations. Related studies are examining conditions such as knee osteoarthritis in people with obesity and metabolic liver disease. Open questions include long-term tolerability, effects on lean mass, and what happens after treatment is stopped.
Clinical development has progressed through phase 2 trials in adults with obesity and type 2 diabetes, with phase 3 programs reported as ongoing. Reported outcomes include reductions in body weight and improvements in glycemic measures over defined treatment periods. Whether these effects translate into durable benefits after treatment ends remains an open question. Long-term safety data across broad populations are not yet complete, and regulatory decisions have not been announced.
Retatrutide is an investigational synthetic peptide engineered to activate three distinct hormone receptors within a single molecule. It targets the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor simultaneously. This triagonist design distinguishes it from earlier incretin-based compounds that act on one or two of these pathways. Structural modifications relative to native gut hormones extend its residence time in circulation. The molecule remains under clinical evaluation and is not approved for any indication.
Peptides in this class degrade mainly through hydrolysis, oxidation, and aggregation. The lipid modification improves plasma residence time but can also promote self-association in aqueous solution at higher concentrations. Oxidation of methionine and deamidation of asparagine residues are common chemical liabilities that accumulate during storage. Stability studies therefore track purity loss, aggregate formation, and changes in receptor-binding potency over time under defined temperature and humidity conditions.
Solid peptide is generally held as a lyophilised powder at low temperature to slow degradation, with desiccant to limit moisture uptake. Reconstituted solutions are less stable and are usually kept refrigerated and protected from light for short periods. Repeated freeze-thaw cycles are avoided because they encourage aggregation. Laboratory handling includes work in a fume hood or laminar flow cabinet to limit inhalation and contamination. Weighing and transfer steps are performed with antistatic tools to reduce static-driven loss of fine powder.
== Treatment == In general, treatment for soft-tissue sarcomas depends on the stage of the cancer. The stage of the sarcoma is based on the size and grade of the tumor, and whether the cancer has spread to the lymph nodes or other parts of the body (metastasized). Treatment options for soft-tissue sarcomas include surgery, radiotherapy, chemotherapy, and targeted drug therapy.
It is thought that in developed countries, the wealthy are able to afford more nutritious food, they are under greater social pressure to remain slim, and have more opportunities along with greater expectations for physical fitness. In undeveloped countries the ability to afford food, high energy expenditure with physical labor, and cultural values favoring a larger body size are believed to contribute to the observed patterns. Attitudes toward body weight held by people in one's life may also play a role in obesity. A correlation in BMI changes over time has been found among friends, siblings, and spouses. Stress and perceived low social status appear to increase risk of obesity. Smoking has a significant effect on an individual's weight. Those who quit smoking gain an average of 4.4 kilograms (9.7 lb) for men and 5.0 kilograms (11.0 lb) for women over ten years. However, changing rates of smoking have had little effect on the overall rates of obesity. In the United States, the number of children a person has is related to their risk of obesity. A woman's risk increases by 7% per child, while a man's risk increases by 4% per child. This could be partly explained by the fact that having dependent children decreases physical activity in Western parents. In the developing world urbanization is playing a role in increasing rate of obesity. In China overall rates of obesity are below 5%; however, in some cities rates of obesity are greater than 20%. In part, this may be because of urban design issues (such as inadequate public spaces for physical activity).
The Decline of Intergenerational Coresidence in the United States, 1850 to 2000. American Sociological Review, vol. 72 (2007), pp. 962–989 Patricia Kelly Hall and Steven Ruggles. 'Restless in the Midst of Their Prosperity': New Evidence on the Internal Migration of Americans, 1850–2000. Journal of American History, vol. 91 (2004), pp. 829–846 Ruggles, Steven. The Rise of Divorce and Separation in the United States, 1880–1990. Demography, vol. 34 (1997), pp. 962–989 Ruggles, Steven. The Transformation of American Family Structure. American Historical Review, vol. 99 (1994), pp. 103–128 Ruggles, Steven. The Origins of African-American Family Structure. American Sociological Review, vol. 59 (1994), pp. 136–151 Ruggles, Steven. Migration, Marriage, and Mortality: Correcting Sources of Bias in English Family Reconstitutions. Population Studies, vol. 46 (1992), pp. 507–522 Ruggles, Steven (1987). Prolonged Connections: The Rise of the Extended Family in Nineteenth-Century England and America. Madison: University of Wisconsin Press. pp. xx, 282. ISBN 0-299-11030-3.
Transfer of sulfur-containing groups is covered by EC 2.8 and is subdivided into the subcategories of sulfurtransferases, sulfotransferases, and CoA-transferases, as well as enzymes that transfer alkylthio groups. A specific group of sulfotransferases are those that use PAPS as a sulfate group donor. Within this group is alcohol sulfotransferase which has a broad targeting capacity. Due to this, alcohol sulfotransferase is also known by several other names including "hydroxysteroid sulfotransferase," "steroid sulfokinase," and "estrogen sulfotransferase." Decreases in its activity has been linked to human liver disease. This transferase acts via the following reaction: 3'-phosphoadenylyl sulfate + an alcohol
Sources: en.wikipedia.org
=== Fine Chemical/Custom Manufacturing Companies === Fine chemical/Custom Manufacturing companies, in a narrow sense, are active in process scale up, pilot plant (trial) production, industrial-scale exclusive and non-exclusive manufacture and marketing. Their product portfolios comprise exclusive products, produced by custom manufacturing, as a main activity, as well as non-exclusive products, such as API-for Generics, and standard products. Characteristics are high asset intensity, batch production in campaigns in multipurpose plants, above-industry-average R&D expenditures and close, multi-level and multi-functional relationships with industrial customers. The industry is very fragmented. 2000 – 3000 fine chemical companies exist globally, extending from small, "garage-type" outfits in China making just one product, all the way to the big, diversified enterprises, resp. units. The main reason for the fragmentation is the lack of economy of scale (see below). The industry is subject to a high degree of regulation, even more so than the chemical industry as a whole, particularly if pharmaceutical fine chemical production is involved. The most important regulatory authorities are the Food and Drug Administration (FDA) in the US, and the State Food & Drug Administration (SFDA) in China. Their main responsibilities include formulating comprehensive supervision policies ("Good Manufacturing Practice"), controlling drug implementation and registration, drawing up criteria for marketing authorization and formulating national essential medicines lists.
== Side effects == In September 2020, the US Food and Drug Administration (FDA) required the boxed warning be updated for all benzodiazepine medicines to describe the risks of abuse, misuse, addiction, physical dependence, and withdrawal reactions consistently across all the medicines in the class.
=== Eukaryotic mRNA turnover === Inside eukaryotic cells, there is a balance between the processes of translation and mRNA decay. Messages that are being actively translated are typically associated with cap-binding and translation initiation factors and with poly(A)-binding protein, which can antagonize deadenylation and decapping and help protect mRNA ends from decay machinery. The balance between translation and decay is reflected in the size and abundance of cytoplasmic structures known as P-bodies. The poly(A) tail of the mRNA is shortened by specialized exonucleases that are targeted to specific messenger RNAs by a combination of cis-regulatory sequences on the RNA and trans-acting RNA-binding proteins. Poly(A) tail removal is thought to disrupt the circular structure of the message and destabilize the cap binding complex. The message is then subject to degradation by either the exosome complex or the decapping complex. In this way, translationally inactive messages can be destroyed quickly, while active messages remain intact. The mechanism by which translation stops and the message is handed-off to decay complexes is not understood in detail. The majority of mRNA decay was believed to be cytoplasmic; however, recently, a novel mRNA decay pathway was described, which starts in the nucleus.
=== Exceptions === Some jellyfish species, including Turritopsis dohrnii, Laodicea undulata, and Aurelia sp.1, are able to revert to the polyp stage even after reproducing (so-called reversible life cycle), rather than dying as in other jellyfish. Consequently, these species are considered biologically immortal and have no maximum lifespan. There may be no natural limit to the hydra's life span, but it is not yet clear how to estimate the age of a specimen. Flatworms, or Platyhelminthes, are known to be "almost immortal" as they have a great regeneration capacity, continuous growth, and binary fission type cellular division. Lobsters are sometimes said to be biologically immortal because they do not seem to slow down, weaken, or lose fertility with age. However, due to the energy needed for moulting, they cannot live indefinitely.
A nerve fascicle is a bundle of nerve fibers belonging to a nerve in the peripheral nervous system. A nerve fascicle is also called a fasciculus. In the central nervous system, the analogous structures are known as nerve tracts.
Sources: en.wikipedia.org
The 3D framework [Cu3(btc)2(H2O)3] (btc: benzene-1,3,5-tricarboxylate) (HKUST-1) used in this study was first reported by Williams et al. The open framework of [Cu3(btc)2(H2O)3] is built from dimeric cupric tetracarboxylate units (paddle-wheels) with aqua molecules coordinating to the axial positions and btc bridging ligands. The resulting framework after removal of two water molecules from axial positions possesses porous channel. This activated MOF catalyzes the trimethylcyanosilylation of benzaldehydes with a low conversion (<5% in 24 h) at 293 K. As the reaction temperature was raised to 313 K, a good conversion of 57% with a selectivity of 89% was obtained after 72 h. In comparison, less than 10% conversion was observed for the background reaction (without MOF) under the same conditions. But this strategy suffers from some problems like 1) the decomposition of the framework with increase of the reaction temperature due to the reduction of Cu(II) to Cu(I) by aldehydes; 2) strong solvent inhibition effect; electron donating solvents such as THF competed with aldehydes for coordination to the Cu(II) sites, and no cyanosilylation product was observed in these solvents; 3) the framework instability in some organic solvents. Several other groups have also reported the use of metal centres in MOFs as catalysts. Again, electron-deficient nature of some metals and metal clusters makes the resulting MOFs efficient oxidation catalysts. Mori and coworkers reported MOFs with Cu2 paddle wheel units as heterogeneous catalysts for the oxidation of alcohols.
By 1906, there were 61 Lodges in Cuba. Independent Lodges who did not desire to recognize the authority of the Grand Lodge still existed in the Eastern half of the island. The Grand Lodge of Cuba considered these Lodges to be clandestine and irregular, completely unwilling to "...submit to Masonic law and cooperate to maintain the high reputation which Cuban Masonry has won after years of struggle..." Between 1902 and 1905, fifty thousand Spaniards from the Iberian Peninsula gained citizenship and residency in the new Cuba. Some of these were willing to join the Grand Lodge of Cuba.
== Ancient eukaryote mechanism == Plants cannot move away from a source of injury as animals do, nor are their immune reactions as elaborate as those in animals. However, there are multiple parallels between plant and animal responses to injury. Both signal damage with calcium ions, which activate receptors to initiate a response. Both also signal damage with reactive oxygen species, which drive metabolic changes, such as enabling cells to multiply to repair damaged tissues. Both have pattern recognition receptors on the surfaces of their cells, triggered by invading pathogens. Both have a "primitive" inflammatory response that releases antimicrobial peptides; additionally, animals have mobile immune cells capable of more complex responses. Both have mechanisms to seal the wound site. Finally, plants and many animals can regenerate some damaged parts. Several of these mechanisms, including receptors, calcium signalling, reactive oxygen species, adenosine triphosphate release, kinase cascades, and oxylipin signalling, are also found in fungi such as Trichoderma. Single-celled eukaryotes, such as choanoflagellates, substantially share the pathways found in plants and animals for detecting damage and pathogens. Extracellular adenosine triphosphate is a signal that promotes healing of wounds to the epithelium in both bilateria (such as vertebrates) and in non-bilaterians such as cnidaria.
Cannabis (), commonly known as marijuana (), weed, pot, Mary Jane, and ganja, among other names, is a non-chemically uniform psychoactive drug from the Cannabis plant. Native to Central or South Asia, cannabis has been used as a drug for both recreational and entheogenic purposes and in various traditional medicines for centuries. Tetrahydrocannabinol (THC) is the main psychoactive component of cannabis, which is one of the 483 known compounds in the plant, including at least 65 other cannabinoids, such as cannabidiol (CBD). Cannabis can be used by smoking, vaporizing, within food, or as an extract. Cannabis has various mental and physical effects, which include euphoria, altered states of mind and sense of time, difficulty concentrating, impaired short-term memory, impaired body movement (balance and fine psychomotor control), relaxation, and an increase in appetite. Onset of effects is felt within minutes when smoked, but may take up to 90 minutes when eaten (as orally consumed drugs must be digested and absorbed). The effects last for two to six hours, depending on the amount used. At high doses, mental effects can include anxiety, delusions (including ideas of reference), hallucinations, panic, paranoia, and cannabis-induced psychotic disorder (CIPD). There is a strong relation between cannabis use and the risk of psychosis, though the direction of causality is debated.
Sources: en.wikipedia.org
It is a synthetic peptide classified as a triple receptor agonist. It engages the GLP-1, GIP, and glucagon receptors at once. It is investigated for metabolic and weight-related conditions rather than approved for general use.
No regulatory agency has approved it for routine medical use. It remains an investigational compound studied in controlled trials. Access outside research settings is not established.
Each receptor influences energy balance through different pathways. Combining them is intended to add fat loss from lowered intake and higher expenditure. The optimal balance among the three effects is still under study.
It is designed as a triple agonist acting on the GLP-1, GIP, and glucagon receptors. This combination is intended to influence appetite, insulin secretion, and energy expenditure. Single-receptor and dual-receptor compounds act on a narrower set of targets.